Recombinant Human Hepatic triacylglycerol lipase (LIPC)

Uniprot Id

P11150

Target Species

Human

Target Name

LIPC

Target Full Name

Hepatic triacylglycerol lipase

Target Function

Catalyzes the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins, including chylomicrons, intermediate density lipoproteins (IDL), low density lipoproteins (LDL) of large size and high density lipoproteins (HDL), releasing free fatty acids (FFA) and smaller lipoprotein particles. Also exhibits lysophospholipase activity. Can hydrolyze both neutral lipid and phospholipid substrates but shows a greater binding affinity for neutral lipid substrates than phospholipid substrates. In native LDL, preferentially hydrolyzes the phosphatidylcholine species containing polyunsaturated fatty acids at sn-2 position.

Target Involvement

Hepatic lipase deficiency (HL deficiency)

Target Subcellular Location

Secreted.

Target Protein Families

AB hydrolase superfamily, Lipase family

Target Synonyms

LIPC; HTGL; Hepatic triacylglycerol lipase; HL; Hepatic lipase; EC 3.1.1.3; Lipase member C

Target Background

Enables phospholipase A1 activity and triglyceride lipase activity. Involved in several processes, including lipid homeostasis; plasma lipoprotein particle remodeling; and triglyceride catabolic process. Located in extracellular space. Implicated in several diseases, including Alzheimer's disease; coronary artery disease; familial combined hyperlipidemia; peripheral vascular disease; and type 2 diabetes mellitus. Biomarker of hyperinsulinism; obesity; and type 1 diabetes mellitus.